87394-62-5

Usage

Chemical Properties

Orange solid

InChI:InChI=1/C9H14N4/c10-8-2-1-3-12-9(8)13-6-4-11-5-7-13/h1-3,11H,4-7,10H2

Upstream product

• 87394-48-7 1-(3-nitro-2-pyridinyl)piperazine 
• 5470-18-8 2-Chloro-3-nitropyridine 

Downstream Products

• 111669-26-2 4-(3-ethylaminopyridin-2-yl)piperazine-1-carboxylic acid tert-butyl ester 
• 111669-24-0 4-[3-(Ethylamino)-2-pyridinyl]-piperazine 
• 111669-25-1 1-[1,1-dimethylethoxycarbonyl]-4-[3-amino-2-pyridinyl]piperazine 

Relevant academic research and scientific papers

PYRIMIDO[5,4-d]PYRIMIDINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS

The present invention relates to pyrimido[5,4-d]pyrimidine derivatives of formula (I), including pharmaceutically acceptable salts and solvates thereof. Compounds of the invention are inhibitors of ENT family transporter, especially of ENT1, and are useful as therapeutic compounds for the treatment of cancers. The invention also relates to the combined use of the pyrimido[5,4-d]pyrimidine derivatives with an adenosine receptor antagonist, for the treatment of cancers.

REMEDIES OR PREVENTIVES FOR AIDS

The present invention is to provide the combined use of one kind or two or more kinds of a quinolone carboxylic acid having anti-HIV activity and one kind or two or more kinds of a reverse transcriptase inhibitor or HIV protease inhibitor, and an AIDS therapeutic agent or preventive agent containing as its active ingredients one kind or two or more kinds of a quinolone carboxylic acid having anti-HIV activity and one kind or two or more kinds of a reverse transcriptase inhibitor or HIV protease inhibitor.

Aryl group- or aromatic heterocyclic group-substituted aminoquinolone derivatives and anti-HIV agent

Disclosed are an aryl group- or heterocyclic group-substituted aminoquinolone compound represented by the formula (Ia), (Ib) or (Ic): STR1 wherein each of the substitutents are defined in the specification, or a salt of the compound, and an AIDS curing agent containing the same as an effective ingredient.

Amines useful in producing pharmaceutically active CNS compounds

Disclosed are Δ9(11) -steroids (VI) and amino substituted steroids (XI) which contain an amino group attached to the terminal carbon atom of the C17 -side chain, more particularly amino steroids (Ia and Ib), aromatic steroids (II), Δ16 -steroids (IIIa and IIIb), reduced A-ring steroids (IV), Δ17(20) -steroids (Va and Vb) and Δ9(11) -steroids (VI) which are useful as pharmaceutical agents for treating a number of conditions.

Amines useful in producing pharmaceutically active CNS compounds

Disclosed are Δ9(11) -steroids (VI) and amino substituted steroids (XI) which contain an amino group attached to the terminal carbon atom of the C17 -side chain, more particularly amino steroids (Ia and Ib), aromatic steroids (II), Δ16 -steroids (IIIa and IIIb), reduced A-ring steroids (IV), Δ17(20) -steroids (Va and Vb) and Δ9(11) -steroids (VI) which are useful as pharmaceutical agents for treating a number of conditions.

Pharmaceutically active amines

The aromatic amines (I), alkyl amines (II), bicyclic amines (III). STR1 cycloalkyl amines (IV), aromatic bicyclic amines (V), hydroquinone amines (VI), quinone amines (VII), amino-ethers (VIII) and bicyclic amino ethers (IX) are useful as pharmaceutical agents for treating a number of conditions including spinal trauma, mild and/or moderate to severe head injury, etc. Also disclosed is a method of treatment using the 3,4-dihydrobenzopyrans (XI).

Amino-9,10-secosteroids useful for treating head injury, spinal cord trauma or stroke

The amino-9,10-secosteroids STR1 of the present invention contain an amino group attached to the terminal carbon atom of the C17 -side chain and are useful as pharmaceutical agents for treating a number of conditions including spinal trauma, mild and/or moderate to severe head injury, etc.

Novel 21-Aminosteroids That Inhibit Iron-Dependent Lipid Peroxidation and Protect against Central Nervous System Trauma

A novel class of 21-aminosteroids has been developed.Compounds within this series are potent inhibitors of iron-dependent lipid peroxidation in rat brain homogenates with IC50's as low as 3 μM.Furthermore, selected members enhance early neurolo

C20 Through C26 amino steroids

Disclosed are Δ9 (11)-steroids (VI) and amino substituted steroids of formula (XI) which contain an amino group attached to the terminal carbon atom of the C17-side chain, more particularly amino steroids (Ia and Ib), aromatic steroids (II), Δ16 (11)-steroids (IIIa and IIIb), reduced A-ring steroids (IV), Δ17 (20)-steroids (Va and Vb) and Δ9 (11)-steroids (VI) which are useful as pharmaceutical agents for treating a number of conditions.

Pyridinylpiperazines, a new class of selective α2-adrenoceptor antagonists

A series of 1-(2-pyridinyl)piperazine derivatives was synthesized and evaluated for adrenergic activity. In vitro activity was assessed through the antagonism of clonidine's effect in the rat, isolated, field-stimulated vas deferens and by the displacemen